胆固醇：有益的、有害的及已停止的试验。 - Suppr

Suppr

超能文献

Cholesterol: the good, the bad, and the stopped trials.

出版信息

Lancet. 2006 Dec 9;368(9552):2034. doi: 10.1016/S0140-6736(06)69815-2.

DOI:10.1016/S0140-6736(06)69815-2

PMID:17161711

Abstract

摘要

相似文献

Cholesterol: the good, the bad, and the stopped trials.

Lancet. 2006 Dec 9;368(9552):2034. doi: 10.1016/S0140-6736(06)69815-2.

The failure of torcetrapib: was it the molecule or the mechanism?

Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):257-60. doi: 10.1161/01.ATV.0000256728.60226.77.

CETP inhibitors to increase HDL cholesterol levels.

N Engl J Med. 2007 Mar 29;356(13):1364-6. doi: 10.1056/NEJMe078029. Epub 2007 Mar 26.

HDL cholesterol and atherosclerosis.

Lancet. 2007 Jul 14;370(9582):107-108. doi: 10.1016/S0140-6736(07)61063-0.

Torcetrapib and coronary events.

N Engl J Med. 2008 Apr 24;358(17):1863; author reply 1863-4.

Torcetrapib and atorvastatin--should marketing drive the research agenda?

N Engl J Med. 2005 Jun 23;352(25):2573-6. doi: 10.1056/NEJMp058075.

[Lowering cholesterol. New concepts with atorvastatin].

Internist (Berl). 1997 Jan;38(1 Suppl):1-8.

Aldosterone, sodium, and hypertension: lessons from torcetrapib?

Hypertension. 2010 Feb;55(2):221-3. doi: 10.1161/HYPERTENSIONAHA.109.146936. Epub 2010 Jan 4.

Development of torcetrapib, a lipid-lowering drug, abandoned.

Prescrire Int. 2007 Jun;16(89):114.

[Regarding LDL cholesterol: the lower, the better (interview by Dr. Dirk Einecke)].

MMW Fortschr Med. 2004 Mar 25;146(13):65.

引用本文的文献

HDL remodeling during the acute phase response.

Arterioscler Thromb Vasc Biol. 2009 Feb;29(2):261-7. doi: 10.1161/ATVBAHA.108.178681. Epub 2008 Nov 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Cholesterol: the good, the bad, and the stopped trials.

Lancet. 2006 Dec 9;368(9552):2034. doi: 10.1016/S0140-6736(06)69815-2.

The failure of torcetrapib: was it the molecule or the mechanism?

Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):257-60. doi: 10.1161/01.ATV.0000256728.60226.77.

CETP inhibitors to increase HDL cholesterol levels.

N Engl J Med. 2007 Mar 29;356(13):1364-6. doi: 10.1056/NEJMe078029. Epub 2007 Mar 26.

HDL cholesterol and atherosclerosis.

Lancet. 2007 Jul 14;370(9582):107-108. doi: 10.1016/S0140-6736(07)61063-0.

Torcetrapib and coronary events.

N Engl J Med. 2008 Apr 24;358(17):1863; author reply 1863-4.

Torcetrapib and atorvastatin--should marketing drive the research agenda?

N Engl J Med. 2005 Jun 23;352(25):2573-6. doi: 10.1056/NEJMp058075.

[Lowering cholesterol. New concepts with atorvastatin].

Internist (Berl). 1997 Jan;38(1 Suppl):1-8.

Aldosterone, sodium, and hypertension: lessons from torcetrapib?

Hypertension. 2010 Feb;55(2):221-3. doi: 10.1161/HYPERTENSIONAHA.109.146936. Epub 2010 Jan 4.

Development of torcetrapib, a lipid-lowering drug, abandoned.

Prescrire Int. 2007 Jun;16(89):114.

[Regarding LDL cholesterol: the lower, the better (interview by Dr. Dirk Einecke)].

MMW Fortschr Med. 2004 Mar 25;146(13):65.

引用本文的文献

HDL remodeling during the acute phase response.

Arterioscler Thromb Vasc Biol. 2009 Feb;29(2):261-7. doi: 10.1161/ATVBAHA.108.178681. Epub 2008 Nov 13.